Profile data is unavailable for this security.
About the company
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.
- Revenue in CHF (TTM)166.98m
- Net income in CHF50.60m
- Incorporated--
- Employees332.00
- LocationCosmo Pharmaceuticals NVRiverside IISir John Rogerson's Quay, Dublin 2DUBLIN IrelandIRL
- Phone+353 18170370
- Websitehttps://www.cosmopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bavarian Nordic A/S | 845.41m | 300.14m | 1.89bn | 1.74k | 6.35 | 1.16 | 4.89 | 2.23 | 30.57 | 30.57 | 85.79 | 168.13 | 0.4732 | 1.34 | 6.08 | 4,274,910.00 | 16.80 | 3.31 | 20.18 | 4.02 | 54.33 | 52.68 | 35.50 | 9.80 | 2.43 | -- | 0.0101 | 0.00 | -19.06 | 53.88 | -33.03 | -- | -8.77 | -- |
| Wockhardt Ltd | 257.15m | -1.98m | 1.95bn | 2.30k | -- | 4.97 | 123.26 | 7.60 | -1.38 | -1.38 | 186.99 | 281.06 | 0.3702 | 1.34 | 4.85 | 12,996,520.00 | -0.4094 | -4.37 | -0.5801 | -7.67 | 65.85 | 56.50 | -1.11 | -11.98 | 1.06 | 1.07 | 0.335 | -- | 7.65 | 1.15 | 89.85 | -- | 16.19 | -- |
| Jinyu Bio-Technology Co Ltd | 148.87m | 11.30m | 1.97bn | 1.74k | 222.39 | 3.21 | -- | 13.23 | 0.071 | 0.071 | 1.27 | 4.92 | 0.1946 | 2.45 | 1.89 | 762,676.30 | 1.37 | 4.31 | 1.56 | 5.06 | 50.46 | 57.76 | 7.02 | 17.99 | 3.09 | -- | 0.0029 | 36.89 | -21.45 | 2.19 | -61.57 | -13.19 | -21.84 | -12.94 |
| Tonghua Dongbao Pharmaceutical Co Ltd | 307.54m | 137.52m | 1.98bn | 3.41k | 14.34 | 2.47 | -- | 6.42 | 0.6271 | 0.6271 | 1.40 | 3.64 | 0.3589 | 1.05 | 5.11 | 803,924.60 | 15.84 | 14.89 | 17.08 | 15.68 | 71.05 | 78.86 | 44.15 | 35.26 | 3.49 | -- | 0.0988 | 50.60 | -34.66 | -6.27 | -103.66 | -- | 14.17 | 4.56 |
| HUTCHMED (China) Ltd | 468.59m | 363.30m | 2.01bn | 1.78k | 5.52 | 2.10 | 5.37 | 4.28 | 4.18 | 4.18 | 5.39 | 11.01 | 0.3966 | 7.09 | 3.86 | 2,597,727.00 | 30.79 | -9.55 | 40.72 | -13.77 | 44.15 | 39.84 | 77.64 | -20.32 | 4.51 | -- | 0.07 | -- | -24.80 | 25.20 | -62.56 | -- | 15.93 | -- |
| Cosmo Pharmaceuticals NV | 166.98m | 50.60m | 2.01bn | 332.00 | 37.68 | 4.33 | 33.07 | 12.04 | 3.04 | 3.04 | 10.25 | 26.45 | 0.292 | 3.64 | 8.05 | 518,884.20 | 8.83 | 4.65 | 9.60 | 5.15 | 73.79 | 68.39 | 30.23 | 26.16 | 3.59 | -- | 0.0058 | 49.72 | 187.55 | 33.68 | 1,335.61 | -- | -20.06 | -- |
| Tarsus Pharmaceuticals Inc | 284.95m | -63.17m | 2.05bn | 323.00 | -- | 7.85 | -- | 7.19 | -2.01 | -2.01 | 8.99 | 7.89 | 0.8039 | 7.39 | 7.19 | 1,133,437.00 | -17.82 | -33.35 | -22.30 | -37.21 | 93.26 | -- | -22.17 | -125.04 | 4.25 | -- | 0.1774 | -- | 948.62 | -- | 14.97 | -- | 106.47 | -- |
| Liaoning Cheng Da Co Ltd | 1.25bn | 96.79m | 2.07bn | 3.32k | 20.96 | 0.6266 | -- | 1.66 | 0.575 | 0.575 | 7.27 | 19.23 | 0.2277 | 5.72 | 5.88 | 3,352,748.00 | 2.94 | 3.15 | 4.13 | 4.55 | 12.07 | 13.95 | 12.89 | 9.88 | 0.9357 | -- | 0.2586 | 16.44 | 4.70 | -8.65 | -10.09 | -29.33 | -9.31 | -27.52 |
| Shandong Buchang Pharmaceuticals Co Ltd | 1.23bn | 186.52k | 2.07bn | 7.69k | 2,565.98 | 1.75 | -- | 1.68 | 0.0068 | 0.0068 | 10.34 | 10.03 | 0.5519 | 0.9196 | 13.73 | 1,425,409.00 | -0.6503 | 0.8521 | -0.9366 | 1.25 | 62.31 | 70.57 | -1.18 | 1.32 | 0.4929 | 3.23 | 0.2758 | 157.32 | -16.91 | -5.04 | -273.62 | -- | -21.53 | -- |
| Shanghai Henlius Biotech Inc | 649.94m | 92.40m | 2.08bn | 3.54k | 35.36 | 8.55 | 14.88 | 3.20 | 1.71 | 1.71 | 12.01 | 7.06 | 0.5386 | 1.73 | 5.86 | 1,856,367.00 | 7.66 | -3.21 | 13.85 | -5.76 | 75.77 | 72.50 | 14.22 | -7.87 | 0.5046 | 10.47 | 0.5185 | -- | 6.11 | 128.98 | 50.26 | -- | 10.83 | -- |
Data as of Feb 06 2026. Currency figures normalised to Cosmo Pharmaceuticals NV's reporting currency: Swiss Franc CHF
10.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 06 Jan 2026 | 540.71k | 3.08% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 328.90k | 1.88% |
| JPMorgan Asset Management (UK) Ltd.as of 31 Dec 2025 | 265.53k | 1.51% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2025 | 216.92k | 1.24% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 124.95k | 0.71% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 103.77k | 0.59% |
| American Century Investment Management, Inc.as of 08 Jan 2026 | 102.51k | 0.58% |
| Valiant Bank AGas of 28 Nov 2025 | 79.32k | 0.45% |
| LLB Asset Management AGas of 31 Dec 2025 | 49.73k | 0.28% |
| Swiss Rock Asset Management AGas of 31 Dec 2025 | 46.56k | 0.27% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
